Genprex

Monthly Archives: October 2018

Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical development programs for the Company’s immunogene therapy, Oncoprex™, which is currently being evaluated in clinical and preclinical studies at MD Anderson Cancer Center for the treatment of non-small cell lung cancer (NSCLC)….

Read More

How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer

The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.

Read More

Genprex to Present at Upcoming Investor and Industry Conferences

AUSTIN,Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:

Event: The MicroCap Conference
Date: October 2, 2018
Time: 12:00 PM EDT
Location: New York, NY
Presenter: Rodney Varner, Chairman and CEO

Event: BIO Investor Forum
Date: October 18, 2018
Time: 9:30 AM PDT
Location: San Francisco, CA
Presenter: Dr….

Read More

How gene therapy is reprogramming the course of lung cancer

How gene therapy is reprogramming the course of lung cancer.

Read More